EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of Combined Therapy with SGLT2i and GLP-1RAs on Atrial Fibrillation Recurrence After Catheter Ablation in Diabetic Cohorts: One-Year Outcomes from Continuous Monitoring

Celestino Sardu iD, Raffaele Marfella iD

International Journal of Molecular Sciences · 23.09.2025 · 26 (19) · 9285

DOI: 10.3390/ijms26199285 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.09.2025. Verfasst von Celestino Sardu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate the effect of sodium–glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and their combination on atrial fibrillation (AF) recurrence after catheter ablation in patients with type 2 diabetes mellitus (T2DM). In a prospective cohort study, patients with T2DM undergoing AF ablation were stratified into three groups: SGLT2i-users, GLP-1RAs-users, and combined SGLT2i/GLP-1RAs users. Diabetics under SGLT2i/GLP-1RAs therapy had worse glycemic control (HbA1c > 7%). AF recurrence was assessed over 12 months using implantable continuous monitoring (ICM). Secondary outcomes included the inflammatory/oxidative stress markers measured at the 12-month follow-up. At the follow-up end, patients treated with SGLT2i/GLP-1RAs versus monotherapy patients showed significantly lower AF recurrence and serum inflammatory/oxidative stress markers, despite having higher HbA1c levels (p < 0.05). Combined SGLT2i/GLP-1RAs therapy reduced AF recurrence following catheter ablation and inflammatory/oxidative stress in T2DM patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHumansMaleFemaleMiddle AgedAgedRecurrenceProspective StudiesTreatment OutcomeDrug Therapy, CombinationOxidative StressGlycated HemoglobinBiomarkers

Stichwörter der Autor:innen

GLP-1RasSGLT2iatrial fibrillationdiabetes mellitus type 2

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinBiomarkers

Autor:innen und Institutionen

  • Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.
  • Pollution and Cardiovascular Diseases Research Centre, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.

ORCID-Profile: Celestino Sardu, Raffaele Marfella

Zitieren

APA

Sardu, C., & Marfella, R. (2025). Effects of Combined Therapy with SGLT2i and GLP-1RAs on Atrial Fibrillation Recurrence After Catheter Ablation in Diabetic Cohorts: One-Year Outcomes from Continuous Monitoring. International Journal of Molecular Sciences, 26(19), 9285. https://doi.org/10.3390/ijms26199285

Vancouver

Sardu C, Marfella R. Effects of Combined Therapy with SGLT2i and GLP-1RAs on Atrial Fibrillation Recurrence After Catheter Ablation in Diabetic Cohorts: One-Year Outcomes from Continuous Monitoring. International Journal of Molecular Sciences. 2025;26(19):9285. doi:10.3390/ijms26199285

BibTeX
@article{Sardu2025,
  author = {Sardu, Celestino and Marfella, Raffaele},
  title = {Effects of Combined Therapy with SGLT2i and GLP-1RAs on Atrial Fibrillation Recurrence After Catheter Ablation in Diabetic Cohorts: One-Year Outcomes from Continuous Monitoring},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {19},
  pages = {9285},
  doi = {10.3390/ijms26199285}
}
Kostenlos starten →